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Studies of the distribution of α1 and α2 subunits of soluble
guanylyl cyclase (sGC) indicate that the α2 subunit is
expressed in relatively high abundance in brain, and is the
major alpha subunit present in the hippocampus. Further-
more, the α2 subunit interacts with a PDZ domain of
PSD95, a scaffolding protein that couples the NMDA
receptor to neuronal nitric oxide synthase. Thus a mem-
brane-bound NO-sensitive sGC is present in the hippoc-
ampus, and has been suggested to be a component of a
signal transduction complex important for modulation of
synaptic transmission and plasticity. We recently com-
pleted a study in which a novel NO mimetic nitrate ester
(GT1061) reversed cognitive deficits in a cholinergic
depletion model of Alzheimer's disease [1]. Of interest
was that comparison of sGC activation in broken cell
preparations of aorta and hippocampus showed that
GT1061 selectively increased enzyme activity in the hip-
pocampus (16- to 20-fold in hippocampus vs. 2- to 3 fold
in aorta), suggesting that the enhanced activation of hip-
pocampal sGC by GT1061 could be due to selectivity of
the drug for targeting the α2β1 isoform of sGC.
In the current study, the activation of sGC by GT1061,
nitroglycerin (GTN), and DEA/NO was examined in vari-
ous subcellular fractions of rat hippocampus (25,000 × g
supernatant fraction, synaptosomes, lysed synaptosomal
supernatant fraction and lysed synaptosomal mem-
branes). In the hippocampal supernatant fraction, maxi-
mal sGC activation by DEA/NO (600-fold) was about 8-
fold and 28-fold greater that that by GTN and GT1061,
respectively. In contrast, the maximal activation by DEA/
NO in hippocampal synaptosomes (15-fold) was only 2–
2.5-fold greater than that by the two nitrate esters. The
majority of the DEA/NO-activated sGC activity was
present in the supernatant fraction, and additionally,
there was a greater potency difference between DEA/NO
and the two nitrates for sGC activation in the supernatant
fraction than there was in the synaptosomes. sGC activity
was further examined after lysis of synaptosomes. Enzyme
activity was present in both the supernatant fraction of
lysed synaptosomes and in synaptosomal membranes,
although the majority of the DEA/NO-activated sGC
activity present in the supernatant fraction. In synapto-
somal membranes, all three compounds increased sGC
activity to the same degree (8–10 fold). Thus the charac-
teristics of hippocampal sGC activation differ markedly
between cytosolic and membrane-bound enzyme, with a
wide variation in efficacy between different nitrovasodila-
tors for activation of cytoplasmic sGC and similar efficacy
for activation of the membrane-bound enzyme. To the
extent that the cognition enhancing properties of GT1061
are due to stimulation of the NO/sGC/cGMP signal trans-
duction system in the hippocampus, the greater relative
efficacy of GT1061 for activation of membrane-bound
hippocampal sGC compared to aortic cytosolic sGC pre-
dicts that the beneficial CNS actions of the drug will occur
at lower plasma concentrations than will any potential
undesirable hypotensive actions. Indeed, improved per-
formance in a visual recognition memory task in cholin-
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ergic-depleted animals occurred at doses of GT1061 that
had negligible effects on systemic blood pressure.
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